The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer. - Abdollahi, Angela; Favata, Margaret; Weber, Michael; Roman, Valerie; Hess, Rodrigo; Hammond, Kayla; Farren, Matthew R.; Schaffer, Mike; Gilmartin, Aidan; Wang, Hui; Rios-Doria, Jonathan; Amador-Arjona, Alejandro (PLoS ONE, 2025)